Pharmacogenomic Susceptibility to Adverse Reactions

Pharmacogenomic susceptibility to adverse reactions is the study of how inherited variation in a patient's genome makes some people more likely than others to be harmed by a medicine. Variants in drug-metabolizing enzymes, transporters, drug targets, and immune-recognition genes can change how much active drug reaches the body or how the body reacts to it, turning an ordinarily tolerable dose into a source of toxicity for a genetically predisposed individual.

Definition

Pharmacogenomic susceptibility to adverse reactions refers to heritable genetic variation that increases an individual's probability of experiencing an adverse drug reaction, typically by altering drug pharmacokinetics (metabolism or transport) or pharmacodynamics (target sensitivity or immune recognition).

Scope

The topic covers the genetic determinants of adverse drug reactions: polymorphisms in metabolizing enzymes such as the cytochrome P450 family and thiopurine S-methyltransferase, HLA alleles linked to severe immune-mediated reactions, and the frameworks that translate this knowledge into guidance. It is presented as a reference account of why genetics modifies drug risk, not as instructions for ordering tests or selecting doses for a particular patient.

Core questions

• Which genetic variants are associated with a higher risk of specific adverse drug reactions?
• How do polymorphisms in metabolizing enzymes alter drug exposure and toxicity?
• Why do some severe immune-mediated reactions depend on particular HLA alleles?
• How is pharmacogenomic evidence graded and translated into prescribing guidance?

Key concepts

• Drug-metabolizing enzyme polymorphism (e.g. CYP2D6, CYP2C19)
• Metabolizer phenotypes (poor, intermediate, extensive, ultrarapid)
• Thiopurine S-methyltransferase (TPMT) variation
• HLA-associated severe cutaneous adverse reactions
• Drug transporter and target variants
• Genotype-phenotype translation
• Evidence grading for pharmacogenomic associations

Mechanisms

Inherited variation affects drug safety through two broad routes. Pharmacokinetically, polymorphisms in metabolizing enzymes (such as CYP2D6, CYP2C19, and TPMT) and in transporters change how rapidly a drug is activated, inactivated, or cleared; a poor-metabolizer genotype can let a standard dose accumulate to toxic concentrations, while an ultrarapid genotype can overproduce an active metabolite. Pharmacodynamically and immunologically, variants in drug targets or in immune-recognition genes alter the body's response: certain HLA class I and class II alleles predispose to severe, immune-mediated cutaneous and hypersensitivity reactions by shaping how a drug or metabolite is presented to T cells. Linking a genotype to a clinically meaningful phenotype, and grading the strength of that link, is central to using the information responsibly (Wang et al., 2011; Phillips et al., 2001; Whirl-Carrillo et al., 2021).

Clinical relevance

Pharmacogenomic susceptibility explains a recognizable subset of serious adverse drug reactions and underlies a growing body of prescribing guidance and label statements. As a reference topic it clarifies why genetically predisposed patients can react badly to standard exposure and how the supporting evidence is evaluated; it is descriptive and is not a protocol for testing or dosing individuals (Phillips et al., 2001; Swen et al., 2011).

Epidemiology

The frequency of risk-conferring variants differs markedly across populations and drug classes, so the contribution of pharmacogenomics to adverse-reaction burden is drug- and ancestry-specific. Systematic appraisal found that a substantial portion of commonly implicated drugs are metabolized by polymorphic enzymes, supporting genetics as one identifiable source of variability in adverse reactions (Phillips et al., 2001).

History

The field grew from mid-twentieth-century observations of inherited differences in drug metabolism (for example in isoniazid acetylation and pseudocholinesterase deficiency) into modern pharmacogenomics, in which genome-wide methods and curated knowledge bases connect specific variants to drug response. Systematic reviews and consensus guideline efforts then organized the evidence so that genotype information could be graded and standardized (Wang et al., 2011; Swen et al., 2011; Whirl-Carrillo et al., 2021).

Debates

How strong must the evidence be before a pharmacogenomic association guides practice?

Associations vary widely in robustness, so frameworks have been developed to grade the level and quality of pharmacogenomic evidence; deciding which variants are actionable remains a matter of explicit evidence appraisal.

Seminal works

• wang-2011
• phillips-2001
• swen-2011

Frequently asked questions

How can genes make a drug dangerous for one person but not another?

Genetic variants can change how fast a drug is broken down or how the immune system reacts to it, so the same dose can build up to toxic levels or trigger a hypersensitivity reaction in a genetically predisposed person.

What kinds of adverse reactions are most linked to genetics?

Two patterns recur: toxicity from drugs cleared by polymorphic enzymes (where slow metabolizers accumulate the drug) and severe immune-mediated skin or hypersensitivity reactions associated with particular HLA alleles.